Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

COVID-19

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Case-Based Roundtable

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Polls

Editorial Advisory Board

Partners

Subscribe

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and is now finishing her Masters in Digital Media through Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family.

Articles

Catch up on coverage from the fourth day of the Maui Derm NP+PA Fall 2024 conference in Nashville, Tennessee.

Day 4 Recap: Maui Derm NP+PA Fall 2024

Hilary Baldwin, MD, emphasized involving patients in the decision-making process to create a personalized and cost-effective plan.

Rosacea Treatment: Letting the Patient Lead the Way

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Data was published in the Journal of the American Board of Family Medicine.

New Data Indicates DermaSensor Effectively Assists Primary Care Clinicians in Differentiating Between Cancerous and Benign Skin Lesions

Allie Karas is the vice president of content for the Health Care Specialty Group division of MJH Life Sciences. She attended Rider University and earned a degree in journalism before pursing a masters in magazine writing from New York University. Prior to making a switch to health care news in 2018, Allie spent 6 years in New York City working in political journalism. She enjoys spending time with her husband and 3 kids, cooking, working out, and her dog Bo. Follow her on Twitter at 

In this Maui Derm NP+PA Fall session, Tsao discusses the growing trend of TIL therapy and neoadjuvant treatment for pigmented lesions, as well as atypical clinical presentation.

Hensin Tsao, MD, PhD: TIL Therapy and Neoadjuvant Treatment for Pigmented Lesions 

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Twitter

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

View

Intermediate dosing of agent may enhance distant metastatis-free intervalfor high-risk patients

clinical

Interferon alfa-2b appears to lesson chances of recurrence